Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Essitol is a brand of aluminum acetate tartrate developed by Athenstaedt, primarily used as a topical anti-inflammatory and astringent for skin conditions. Although it is supplied in a tablet dosage form, it is not intended for oral ingestion; rather, the tablets are designed to be dissolved in water to prepare cooling compresses (Umschläge). The active ingredient, aluminum acetate tartrate, works by non-specifically precipitating proteins on the skin surface and within superficial tissue layers. This astringent action leads to the constriction of local capillaries, a reduction in tissue permeability, and the stabilization of cell membranes, which effectively alleviates swelling, itching, and inflammation. It is commonly indicated for the treatment of localized skin irritations, such as insect bites, minor burns, and blunt injuries (e.g., bruises or sprains).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aluminum acetate tartrate.